http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
李順愛 慶尙大學校 1996 論文集 Vol.35 No.2
Background : A malignant ovarian tumor is one of the most frequently occurring gynecololgic cancer in USA, measuring about 25% among all gynecologic cancers. Diagnosis of ovarian cancer is difficult because there are lack of specific initial symptoms or signs especially among the patients in early stages of disease. And also, it is not well known what the exact causes are. There are some studies on ovarian cancers in Korea. This study will be the one. Objective : The aim of this study is to investigate the clinical and pathological features of malignant ovarian tumors. And we may applicate its results to early detection or appropriate management for those who have ovarian malignancy. Method : A clinico-pathological study was made on series of 53 malignant ovarian tumors which were operated and confirmed by postoperative histopathologic study at department of Obstetrics and gynecology in GyeongSang National University Hospital during a period of 8 years and 9 months, from March 1987 to December 1995. 1. Age distribution of malignant ovarian tumors showed the highest frequency in 7th decade and the average age was 62.5 years. 2. The frequency of nulliparity was 28.3% and the primary infertility rate was 11.4%. 3. Previous menstrual cycles of menstruating group has been abnormal in 9.4%, postmenopausal group in 53% and prepubertal group in 3.8%. 4. The subjective symptoms were abdominal mass palption(22.7%), abdominal destension(17%), abdominal(13.2%) The interval from noset of symptoms to diagnosis was 6 months or less in 76.1%. 5. Bilaterality was noted in 37.7% by gross of microscopic examination. 6. Histologic incidence were as follows : malignant epithelial tumors in 69.6%, germ cell tumors in 9.5%, sex cord stromal tumors in 7.6% and metastatic tumors in 11.4%, and of the malignant epithelial tumors, mucinous carcinoma in 31.9%, serous carcinoma in 31.5%, endometrioid carcinoma in 3.8% and MMMT in 3.8%. 7. According to FIGO staging of primary ovarian tumor, stage I in 56%, stage II in 16%, stage III in 22% and stage IV in 6%. 8. Tumor marker, CA-125 was increased in 87.5% of serous carcinoma, 52.9% of mucinous carcinoma, 50% of endometrioid carcinoma and 50% of sex-cord stromal tumors. CA-125 was increased in 53.6% of stage I disease, 75% of stage II, and 100% of the stage III and IV disease. 9. Total abdominal hysterectomy with salpingo-oophorectomy was performed in 57.4%, and omentectomy in 73.6%.
이순애,김혜정,장기철,백종철,박지권,신정규,최원준,이종학,백원영 대한약리학회 2009 The Korean Journal of Physiology & Pharmacology Vol.13 No.4
Inflammatory processes of vascular endothelial cells play a key role in the development ofatherosclerosis. We determined the anti-inflammatory effects and mechanisms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on LPS-treated human umbilical vein endothelial cells (HUVECs) to evaluate their cardioprotective potential. Cells were pretreated with DHA, EPA, or troglitazone prior to activation with LPS. Expression of COX-2, prostaglandin E2 (PGE2) and IL-6 production, and NF-κB activity were measured by Western blot, ELISA, and luciferase activity, respectively. Results showed that EPA, DHA, or troglitazone significantly reduced COX-2 expression, NF-κB luciferase activity, and PGE2 and IL-6 production in a dose-dependent fashion. Interestingly, low doses (10μM) of DHA and EPA, but not troglitozone, significantly increased the activity of NF-κB in resting HUVECs. Our study suggests that while DHA, EPA, and troglitazone may be protective on HUVECs under inflammatory conditions in a dose-dependent manner. However there may be some negative effects when the concentrations are abnormally low, even in normal endothelium.